Immatics PRAME Programs Show 32% and 41% Response Rates in Early Solid-Tumor Trials
IMTX is trading near its 52-week low of $6.65 (9.9% above the low).
Summary
Immatics posted Phase 1b IMA402 data with a 32% confirmed objective response rate in PRAME-high melanoma and 25% overall (n=40), plus 91% one-year overall survival at the recommended Phase 2 dose versus 60% below it. The separate IMA203CD8 cell therapy showed a 41% cORR across 87 patients and 55% in 20 gynecologic cancer patients. Safety was manageable with no Grade 5 events and mostly low-grade cytokine release syndrome, which keeps combination studies and targeted cohorts on the table. These are early, single-arm signals in refractory settings, so they validate the PRAME franchise but do not yet prove durable benefit. The company entered this readout with $448.2M in cash and runway into 2028 following its $150M August offering, so financing is not the near-term constraint. Next step is randomized or registrational data and regulatory agreement on a path to approval.
At the time of this announcement, IMTX was trading at $7.31 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $1.1B. The 52-week trading range was $6.65 to $12.41. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: Wiseek News.